3-(4-iodophenyl)pentan-3-ol | 700832-79-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-iodophenyl)pentan-3-ol
• 英文别名: 3'-(4-iodophenyl)-3'-pentanol
• CAS: 700832-79-7
• 化学式: C₁₁H₁₅IO
• 分子量: 290.144
• InChiKey: PFRWQWGYPDRYFG-UHFFFAOYSA-N

物化性质

• 沸点：
  320.8±25.0 °C(Predicted)
• 密度：
  1.509±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(4-iodophenyl)pentan-3-ol 在 盐酸 、 1,1'-双(二苯基膦)二茂铁 、 硫酸 、 水 、 palladium diacetate 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 30.0h， 生成 ethyl 4-[1-ethyl-1-({[(5R)-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo-[1,5-a]-pyrimidin-3-yl]carbonyl}amino)propyl]benzoate
  参考文献：
  名称：

  Novel and potent calcium-sensing receptor antagonists: Discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent

  摘要：

  The calcium-sensing receptor antagonist (CaSR) has been recognized as a promising target of anabolic agents for treating osteoporosis. In the course of developing a new drug candidate for osteoporosis, we found tetrahydropyrazolopyrimidine derivative 1 to be an orally active CaSR antagonist that stimulated transient PTH secretion in rats. However, compound 1 showed poor physical and chemical stability. In order to work out this compound's chemical stability and further understand its in vivo efficacy, we focused on modifying the 2-position of the tetrahydropyrazolopyrimidine. As a result of chemical modification, we discovered (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate 10m (TAK-075), which showed improved solubility, chemical stability, and in vivo efficacy. Furthermore, we describe that evaluating the active metabolite is important during repeated treatment with short-acting CaSR antagonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.02.001
• 作为产物：
  描述：

  对碘苯甲酸乙酯 在 乙基溴化镁 作用下， 以 乙醚 为溶剂， 以90%的产率得到3-(4-iodophenyl)pentan-3-ol
  参考文献：
  名称：

  [EN] VITAMIN D RECEPTOR MODULATORS
  [FR] MODULATEURS DE RECEPTEUR DE VITAMINE D

  摘要：

  本发明涉及一种新颖的、非类固醇的、二芳基化合物，具有维生素D受体（VDR）调节活性，比1a,25二羟基维生素D3更少引起高钙血症。这些化合物可用于治疗骨疾病和牛皮癣。

  公开号：

  WO2004048309A1

文献信息

• Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
  申请人：Nagpal Sunil

  公开号：US20060094778A1

  公开（公告）日：2006-05-04

  The present invention relates to a method of treating or preventing damage to human skin cells by chemical vesicants by administering a non-secosteroidal, diphenyl compound with vitamin D receptor (VDR) modulating activity.

  本发明涉及一种通过给予一种具有维生素D受体（VDR）调节活性的非类固醇二苯基化合物来治疗或预防化学性水疱剂对人体皮肤细胞的损伤的方法。
• Vitamin D Receptor Modulators
  申请人：Bunel Emilio Enrique

  公开号：US20090018058A1

  公开（公告）日：2009-01-15

  The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating and psoriasis.

  本发明涉及一种新型的非类固醇二芳基化合物，具有维生素D受体（VDR）调节和治疗牛皮癣的作用。
• VITAMIN D RECEPTOR MODULATORS
  申请人：Bunel Emilio Enrique

  公开号：US20090227604A1

  公开（公告）日：2009-09-10

  The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

  本发明涉及一种新的、非次级甾体、二芳基化合物，具有维生素D受体（VDR）调节活性，比1a,25二羟基维生素D3的高钙血症更少。这些化合物对治疗骨病和牛皮癣有用。
• VESICANT TREATMENT WITH PHENYL-PHENYL TYPE VITAMIN D RECEPTOR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1587906A2

  公开（公告）日：2005-10-26
• US3957871A
  申请人：——

  公开号：US3957871A

  公开（公告）日：1976-05-18